{"id":576,"date":"2018-01-18T13:27:51","date_gmt":"2018-01-18T13:27:51","guid":{"rendered":"http:\/\/cardusocapital.com\/?p=576"},"modified":"2018-03-05T15:30:30","modified_gmt":"2018-03-05T15:30:30","slug":"biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program","status":"publish","type":"post","link":"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/","title":{"rendered":"BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its \u20ac 1.0 million cardiac fibrosis imaging program."},"content":{"rendered":"<p>Groningen, The Netherlands, December 14, 2017<\/p>\n<p>An EFRO TENDER VALORISATIE 2017 grant of a EUR 1.0 million cardiac fibrosis imaging program is\u00a0awarded to BiOrion Technologies BV. The grant will be used for the preparation and execution of a\u00a0clinical phase 0 imaging study in cardiac fibrosis patients and the preclinical development of a\u00a0targeted therapeutic, with BiOrion\u2019s PDGF beta receptor binding bicyclic peptide conjugates.\u00a0EFRO TENDER VALORISATIE 2017 is a program of the European Regional Development Fund from the\u00a0European Commission, co-funded from the national budgets of Participating States, Partner\u00a0Countries and by the European Union through Horizon 2020.<\/p>\n<hr id=\"system-readmore\" \/>\n<p><img decoding=\"async\" src=\"images\/press-release.jpg\" alt=\"\" \/>Herman Steen, CEO of BiOrion, said &#8220;This European Union EFRO grant will further enable BiOrion to\u00a0progress its clinical development of its novel myofibroblast targeting platform. It is an ongoing\u00a0recognition and support for our PDGF-beta-receptor binding bicyclic peptide drug-conjugates\u00a0technology.\u201d<\/p>\n<p><strong> About BiOrion Technologies<\/strong><br \/>\nBiOrion is a Dutch clinical stage biopharmaceutical drug discovery company founded in 2007,\u00a0engaged in developing targeted therapeutics and companion imaging diagnostics for fibrotic<br \/>\ndiseases. These diseases include cardiac fibrosis, hepatic fibrosis, and fibrosis-associated cancers\u00a0such as colorectal cancer. BiOrion&#8217;s platform and drug development engine is based on proprietary\u00a0PDGF-beta-receptor binding bicyclic peptides that act as targeting vehicles for diagnostic PET\u00a0radionuclides and (existing) anti-fibrotic therapeutics.<\/p>\n<p><strong>Contact<\/strong><br \/>\nHerman Steen, PhD<br \/>\nCEO BiOrion Technologies BV<br \/>\n<a href=\"mailto:herman.steen@biorion.com\">herman.steen@biorion.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Groningen, The Netherlands, December 14, 2017 An EFRO TENDER VALORISATIE 2017 grant of a EUR 1.0 million cardiac fibrosis imaging program is\u00a0awarded to BiOrion Technologies BV. The grant will be used for the preparation and execution of a\u00a0clinical phase 0 imaging study in cardiac fibrosis patients and the preclinical development of a\u00a0targeted therapeutic, with BiOrion\u2019s [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[6],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v19.10 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its \u20ac 1.0 million cardiac fibrosis imaging program. - Carduso Capital<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its \u20ac 1.0 million cardiac fibrosis imaging program. - Carduso Capital\" \/>\n<meta property=\"og:description\" content=\"Groningen, The Netherlands, December 14, 2017 An EFRO TENDER VALORISATIE 2017 grant of a EUR 1.0 million cardiac fibrosis imaging program is\u00a0awarded to BiOrion Technologies BV. The grant will be used for the preparation and execution of a\u00a0clinical phase 0 imaging study in cardiac fibrosis patients and the preclinical development of a\u00a0targeted therapeutic, with BiOrion\u2019s [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Carduso Capital\" \/>\n<meta property=\"article:published_time\" content=\"2018-01-18T13:27:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2018-03-05T15:30:30+00:00\" \/>\n<meta name=\"author\" content=\"webmaster\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Geschreven door\" \/>\n\t<meta name=\"twitter:data1\" content=\"webmaster\" \/>\n\t<meta name=\"twitter:label2\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minuut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/\",\"url\":\"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/\",\"name\":\"BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its \u20ac 1.0 million cardiac fibrosis imaging program. - Carduso Capital\",\"isPartOf\":{\"@id\":\"https:\/\/cardusocapital.com\/#website\"},\"datePublished\":\"2018-01-18T13:27:51+00:00\",\"dateModified\":\"2018-03-05T15:30:30+00:00\",\"author\":{\"@id\":\"https:\/\/cardusocapital.com\/#\/schema\/person\/8423bd23fd340884b367a242f66a84c3\"},\"breadcrumb\":{\"@id\":\"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/#breadcrumb\"},\"inLanguage\":\"nl\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cardusocapital.com\/nl\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its \u20ac 1.0 million cardiac fibrosis imaging program.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cardusocapital.com\/#website\",\"url\":\"https:\/\/cardusocapital.com\/\",\"name\":\"Carduso Capital\",\"description\":\"Where Science becomes Business\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cardusocapital.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"nl\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cardusocapital.com\/#\/schema\/person\/8423bd23fd340884b367a242f66a84c3\",\"name\":\"webmaster\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its \u20ac 1.0 million cardiac fibrosis imaging program. - Carduso Capital","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/","og_locale":"nl_NL","og_type":"article","og_title":"BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its \u20ac 1.0 million cardiac fibrosis imaging program. - Carduso Capital","og_description":"Groningen, The Netherlands, December 14, 2017 An EFRO TENDER VALORISATIE 2017 grant of a EUR 1.0 million cardiac fibrosis imaging program is\u00a0awarded to BiOrion Technologies BV. The grant will be used for the preparation and execution of a\u00a0clinical phase 0 imaging study in cardiac fibrosis patients and the preclinical development of a\u00a0targeted therapeutic, with BiOrion\u2019s [&hellip;]","og_url":"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/","og_site_name":"Carduso Capital","article_published_time":"2018-01-18T13:27:51+00:00","article_modified_time":"2018-03-05T15:30:30+00:00","author":"webmaster","twitter_card":"summary_large_image","twitter_misc":{"Geschreven door":"webmaster","Geschatte leestijd":"1 minuut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/","url":"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/","name":"BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its \u20ac 1.0 million cardiac fibrosis imaging program. - Carduso Capital","isPartOf":{"@id":"https:\/\/cardusocapital.com\/#website"},"datePublished":"2018-01-18T13:27:51+00:00","dateModified":"2018-03-05T15:30:30+00:00","author":{"@id":"https:\/\/cardusocapital.com\/#\/schema\/person\/8423bd23fd340884b367a242f66a84c3"},"breadcrumb":{"@id":"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/#breadcrumb"},"inLanguage":"nl","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/cardusocapital.com\/nl\/biorion-technologies-receives-an-efro-tender-valorisatie-2017-grant-for-its-e-1-0-million-cardiac-fibrosis-imaging-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cardusocapital.com\/nl\/"},{"@type":"ListItem","position":2,"name":"BiOrion Technologies receives an EFRO TENDER VALORISATIE 2017 grant for its \u20ac 1.0 million cardiac fibrosis imaging program."}]},{"@type":"WebSite","@id":"https:\/\/cardusocapital.com\/#website","url":"https:\/\/cardusocapital.com\/","name":"Carduso Capital","description":"Where Science becomes Business","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cardusocapital.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"nl"},{"@type":"Person","@id":"https:\/\/cardusocapital.com\/#\/schema\/person\/8423bd23fd340884b367a242f66a84c3","name":"webmaster"}]}},"_links":{"self":[{"href":"https:\/\/cardusocapital.com\/nl\/wp-json\/wp\/v2\/posts\/576"}],"collection":[{"href":"https:\/\/cardusocapital.com\/nl\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cardusocapital.com\/nl\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cardusocapital.com\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/cardusocapital.com\/nl\/wp-json\/wp\/v2\/comments?post=576"}],"version-history":[{"count":2,"href":"https:\/\/cardusocapital.com\/nl\/wp-json\/wp\/v2\/posts\/576\/revisions"}],"predecessor-version":[{"id":611,"href":"https:\/\/cardusocapital.com\/nl\/wp-json\/wp\/v2\/posts\/576\/revisions\/611"}],"wp:attachment":[{"href":"https:\/\/cardusocapital.com\/nl\/wp-json\/wp\/v2\/media?parent=576"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cardusocapital.com\/nl\/wp-json\/wp\/v2\/categories?post=576"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cardusocapital.com\/nl\/wp-json\/wp\/v2\/tags?post=576"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}